li>Partner with Total Rewards and HR leaders to design, configure, and optimize scalable Workday Advanced Compensation solutions, serving as the functional lead and subject matter expert for compensation plans, eligibility rules, compensation cycles, bonus and equity processes, security, and related governance. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.